Syndax closes $230M public offering of common stock at $18.50/share

Syndax Pharmaceuticals Inc

Offering of 12,432,431 shares includes full exercise of underwriters' option to purchase 1,621,621 additional shares.
Gross proceeds of approximately $230M; net proceeds after underwriting discounts and expenses expected.
Post-offering shares outstanding as of Dec 19, 2023: 84,809,736.
Goldman Sachs, J.P. Morgan, TD Cowen, and Stifel acted as joint book-running managers.
Offering made under an existing effective shelf registration statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.